Ionis share price
Web26 jul. 2024 · To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma. Ionis' Forward-looking Statement. This press release includes forward-looking statements regarding Ionis’ business and the therapeutic and commercial potential of Ionis' technologies, IONIS-MAPTRx/BIIB080 and other products in development. WebIn May 2016, Ionis licensed the rights to the drug to Kastle Therapeutics for $15 million upfront with another $10 million due in May 2024, up to $70 million in milestones based …
Ionis share price
Did you know?
Web9 nov. 2024 · For the nine months ended September 30, 2024 Ionis recognized $1.4 million and $1.5 million of medical affairs expenses and commercialization expenses for eplontersen, respectively, net of cost-share funding from AstraZeneca. Ionis expects its medical affairs and commercialization expenses to increase as this collaboration … Web13 apr. 2024 · IONS.OQ - Stock Price & Latest News Reuters SPX 4,105.02+0.36% IXIC 12,087.96+0.76% DJI 33,485.29+0.01% STOXX 458.94+0.51% FTSE 7,741.56+1.03% …
Web1 apr. 2024 · IONIS PHARMACEUTICALS INC stock price forecast for further price development up to 0. ... 1 day) and price target of 36.61 USD. Positive news sentiment. Short-term (time horizon: 2 weeks) IONIS PHARMACEUTICALS INC share price prediction for 2024-05-26 with daily closed price projections Key Facts Symbol IONS ISIN … Web19 mrt. 2024 · Ionis' sales price and market cap have been guilty of long-term loitering. Despite its proven ability to earn growing revenues and its unmatched pipeline validated by some 10 partnership deals...
WebMarket capitalization of Ionis Pharmaceuticals (IONS) Market cap: $5.32 Billion As of April 2024 Ionis Pharmaceuticals has a market cap of $5.32 Billion . This makes Ionis … WebThe latest Ionis Pharmaceuticals Inc Common Stock USD0.001 share price. View recent trades and share price information for Ionis Pharmaceuticals Inc Common Stock …
Web24 mrt. 2024 · After this action, Monia Brett P now owns 145,305 shares of Ionis Pharmaceuticals Inc., valued at $1,003,153 using the latest closing price. HOUGEN ELIZABETH L, the EVP, Finance & CFO of Ionis Pharmaceuticals Inc., sale 2,079 shares at $40.59 during a trade that took place back on Feb 06, which means that HOUGEN …
Web22 feb. 2024 · For the year ended December 31, 2024 Ionis recognized $2.0 million and $2.6 million of medical affairs expenses and commercialization expenses for eplontersen, respectively, net of cost … bisley clay shooting pay and playWeb22 feb. 2024 · R&D revenue for 2024 included $112 million from Biogen for advancing several neurology disease programs, $77 million from AstraZeneca for its share of the … bisley c of e primary school term datesWeb9 apr. 2024 · Their IONS share price forecasts range from $27.00 to $67.00. On average, they predict the company's share price to reach $45.17 in the next year. This suggests a … bisley collection cabinetsWeb12 apr. 2024 · About IONS. Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal … bisley c of e schoolWebIONS: Ionis Pharmaceuticals Inc Stock Price Quote - NASDAQ GS - Bloomberg Bloomberg TV+ Bloomberg Daybreak Europe Bloomberg Daybreak Europe. Live from London, tracking the breaking and... bisley c of eWeb22 feb. 2024 · For the year ended December 31, 2024 Ionis recognized $2.0 million and $2.6 million of medical affairs expenses and commercialization expenses for eplontersen, respectively, net of cost-share funding from AstraZeneca. Ionis expects its medical affairs and commercialization expenses to increase as this collaboration progresses. bisley coltdarleane c. hoffman ph.d